BYSI - BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution
- BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone.
- However, the company is in perpetual cash-hungry mode, and every time it raises cash, the stock suffers.
- Catalysts are about a year ahead, but dilution is a worry.
For further details see:
BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution